title: Osteoporosis diagnosis and medical treatment.
abstract: Osteoporosis, the presence of either low bone mineral density or a history of a fragility fracture, is known to be associated with an increased risk of future fracture. Fracture prevention is possible through use of both nonpharmacologic and prescription treatments. Despite recent controversy regarding the safety of calcium supplementation and the appropriate dosing of calcium and vitamin D, calcium and vitamin D remain an important part of bone health. However, prescription osteoporosis treatments should be considered for those at higher risk for fracture, and there are currently several treatment options available.
authors.affiliation: Division of Endocrinology, Metabolism and Diabetes, University of Alabama at Birmingham, Birmingham, AL 35233, USA. warriner@uab.edu
authors.forename: Amy H
authors.initials: AH
authors.lastname: Warriner
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Saag
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D006620:Hip Fractures / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D058866:Osteoporotic Fractures / Q000453:epidemiology; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D012008:Recurrence; D018570:Risk Assessment; D019379:Teriparatide / Q000008:administration & dosage; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D053245:RANK Ligand; D019379:Teriparatide; D014807:Vitamin D; D000069448:Denosumab; D002118:Calcium